OptimizeRx Q1 Revenue Beats Estimates at $19.8M; Adjusted Net Income and EBITDA Turn Profit from Expected Loss
Summary
OptimizeRx reported strong Q1 2026 results, with revenue reaching $19.8 million, surpassing the IBES estimate of $18.4 million. Critically, the company achieved adjusted net income of $2.7 million and adjusted EBITDA of $3.3 million, significantly outperforming analyst estimates that projected losses of $31.2 thousand and $193 thousand, respectively. This performance builds on the positive financial turnaround reported in the 2025 10-K, demonstrating continued operational strength. The substantial beat on profitability, converting expected losses into solid gains, is a highly material positive surprise for a company of OptimizeRx's size, indicating robust execution and strong demand for its services. Traders will be closely watching for management's outlook on the sustainability of these margins and any updated full-year guidance.
At the time of this announcement, OPRX was trading at $6.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $119M. The 52-week trading range was $5.54 to $22.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.